On Apr. 1, 1993, the FDA approved Amgen’s Epogen/Procrit for the treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy. Epogen was first approved in 1989 for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis.